Puma Plummets On Another Neratinib NDA Delay
This article was originally published in Scrip
Executive Summary
Puma Biotechnology Inc. fell 21.1% to close at $27.92 per share on March 29 after it revealed a second major delay for the company's new drug application (NDA) submission to the US FDA for neratinib as an extended adjuvant treatment for early-stage HER2-positive breast cancer.
You may also be interested in...
Puma's Neratinib SUMMIT Study Shows Potential & Pitfalls Of Precision Medicine
"Basket trial" design allowed Puma to identify certain cohorts for further study, but also missed in areas where neratinib was expected to work.
Keeping Track: Approval Elusive For Biosimilar Neulasta; Valeant Gets A Nod And A No From FDA; Submissions From Amgen, Puma, Bristol
The latest drug development news and highlights from our FDA Performance Tracker
Ionis Closer To First Wholly-Owned Drug Launch With Olezarsen Phase III Success
Ionis will seek US and EU approvals to treat familial chylomicronemia syndrome in the first half of 2024. Phase III data in the larger severe hypertriglyceridemia indication are due in late 2024 or early 2025.